Pliant Therapeutics, Inc.
PLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $2 | $10 | $8 |
| % Growth | -100% | -83.7% | 27.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $2 | $10 | $8 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $169 | $128 | $97 | $78 |
| G&A Expenses | $59 | $58 | $40 | $28 |
| SG&A Expenses | $59 | $58 | $40 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $228 | $186 | $137 | $105 |
| Operating Income | -$228 | -$184 | -$127 | -$98 |
| % Margin | – | -11,654.7% | -1,313.4% | -1,288.1% |
| Other Income/Exp. Net | $18 | $23 | $4 | $0 |
| Pre-Tax Income | -$210 | -$161 | -$123 | -$97 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$210 | -$161 | -$123 | -$97 |
| % Margin | – | -10,211.1% | -1,273.3% | -1,284.5% |
| EPS | -3.47 | -2.75 | -2.94 | -2.71 |
| % Growth | -26.2% | 6.5% | -8.5% | – |
| EPS Diluted | -3.47 | -2.75 | -2.94 | -2.71 |
| Weighted Avg Shares Out | 61 | 59 | 42 | 36 |
| Weighted Avg Shares Out Dil | 61 | 59 | 42 | 36 |
| Supplemental Information | – | – | – | – |
| Interest Income | $21 | $24 | $5 | $0 |
| Interest Expense | $3 | $1 | $1 | $0 |
| Depreciation & Amortization | $2 | $2 | $4 | $2 |
| EBITDA | -$205 | -$158 | -$119 | -$96 |
| % Margin | – | -10,014.4% | -1,227.1% | -1,264.2% |